thumbnail image
broken image
broken image
broken image
  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • TROY-Ig TCE platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • TROY-Ig TCE platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
broken image
broken image
broken image
  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • TROY-Ig TCE platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • TROY-Ig TCE platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
broken image
  • LVGN3616

    Anti-PD-1 blocking monoclonal antibody

  • A primary function of the immune system is to determine which cells or substances are self or non-self. The immune system only makes enough white blood cells to fight non-self antigens present in the body. After an at­tack, the immune system must slow down. It does this through the use of checkpoints.
    Co-inhibitory checkpoints keep the immune system “in check,” preventing an attack on normal cells by using regulatory T-cells and other mechanisms. When the correct proteins and cell receptors connect, a series of signals is sent to the immune sys­tem to slow down once an immune response is finished. Three checkpoint receptors that slow down the immune system have been identified for their roles in cancer treatment: CTLA4, PD-1 and PD-L1.
    PD-1 (programmed cell death protein 1) is a receptor involved with telling T-cells to die and to reduce the death of regulatory T-cells (suppressor T-cells). Both slow down an immune response. PD-1 can tell the immune system to slow down only if it connects with PD-L1.
       Anti-PD-1 antibody LVGN3616 blocks the connection between PD-1 and PD-L1, allow for the continued or increased production of T-cells and enable them to continue fighting cancer.
    Contact us

    Lyvgen website is designed to provide general information about the subject matter presented. The information presented does not, and is not intended to, provide medical advice.

沪公网安备 31011502015346号
|
沪ICP备20018873号-2
    Home
    About us
    xLinkAb
    Contact us
Lyvgen Biopharma Website 礼进生物 英文官网
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.
https://user-assets.sxlcdn.com/images/676507/FiTA8WK-FQRyXrQDyd-HDkY3tpfI.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
Cookie的使用
我们使用cookies来确保流畅的浏览体验。若继续,我们认为你接受使用cookies。
了解更多